With Cortex having to raise $5 mil from vultures just to keep the doors open, I'd be more worried about Cortex surviving as a company than whether you would sell at $20 or $30 in ten years. Not to be overly negative, but let's get real.
Unlike Neuro's rosy 70% estimate for restoring CX-717/ADHD, in my mind I'm finding it hard to justify anything over 20% (and I'm trending more toward 10%). We won't know til June or so, so there's plenty of time to debate the topic. Any additional info Dr. Stoll can provide after all the new data is analyzed may help us estimate the odds. No matter how you slice it though, odds-wise, the FDA decision is going to be a crapshoot at best.
Market Data 
Markets 
AI
